Overview

Efaproxiral Plus Carmustine in Treating Patients With Progressive or Recurrent Malignant Glioma

Status:
Completed
Trial end date:
2006-10-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. PURPOSE: This phase I/II trial is studying the side effects and best dose of efaproxiral when given with carmustine and to see how well they work in treating patients with progressive or recurrent malignant glioma.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
New Approaches to Brain Tumor Therapy Consortium
Collaborator:
National Cancer Institute (NCI)
Treatments:
Carmustine
Efaproxiral